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Genetic ablation studies confirmed the role of central insulin-receptor signaling (CIRS) in fuel 
metabolism. However, the need to examine the role of CIRS in glucose homeostasis under normal 
physiological condition is indispensable, as insulin affects the neuronal growth, differentiation and 
synaptic plasticity. Intracerebral administration of S961 induced hyperglycemia and glucose 
intolerance in normal rats, and provided direct evidence for the involvement of CIRS in the 
regulation of glucose homeostasis. 
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Previous studies employing genetically-engineered models provided convincing evidence for the 
role of CIRS in food intake, fuel metabolism and reproduction 1-3. However, the altered insulin 
signaling in brain during developmental phase may account for some of insulin's biological 
consequences, as it is known to affect the neuronal growth, differentiation, neurotransmitter release 
and synaptic plasticity4-7. The importance of the acute inhibition of CIRS in the regulation of glucose 
homeostasis under normal physiological condition remained to be delineated. 
To address this vital question, a novel high-affinity insulin-receptor antagonist S9618 was 
intracerebrally (IC) administered in the normal adult Sprague-Dawley rats (200 ± 10 g). IC 
administration of S961 led to significant increase in the plasma glucose level. Although, S961 at the 
dose of 3 μg induced significant increase in the plasma glucose level 2 h after IC administration, the 
failure to elicit comparable response at the same dose with intravenous (IV) administration 
confirmed the role of CIRS on the glucose level. Based on the previous experiments9, the secondary 
rise in the plasma insulin level can be speculated as a possible reason for the absence of 
hyperglycemic response at the  lower dose of S961 (3 μg) and failure of adequate hyperinsulinemic 
compensation at the higher dose (10μg). Further, the acute inhibition of CIRS led to impairment in 
the glucose tolerance as evident from higher glucose level over a period of time (Fig. 1). 
Synchronous functioning of peripheral tissues including muscle, liver, adipose-tissue and pancreas 
(islet of Langerhans)  maintains the plasma glucose level in the short range of variation (4 to 7mM) 
in normal individuals, despite periods of feeding and fasting 10, 11. More than a century ago, eminent 
physiologist Claude Bernard observed that puncture in the fourth cerebral ventricle could induce 
diabetes in animals12. Although this exceptional finding provides reasonable evidence for the 
involvement of central nervous system in the glucose homeostasis, its importance has not been 
recognized till identification of insulin-receptors in the brain 13. However, recent findings provide 
the compelling evidence for the role of CIRS in the glucose homeostasis 2, 3. In consistence with the 
previous findings highlighting the role of CIRS in glucose homeostasis using genetic ablation 
studies1-3, 14, 15, the present results provide direct evidence for the involvement of brain in the glucose 
homeostasis in genetically unmodified animals. Further, the study demonstrates the relatively easy, 
direct and an economic means to investigate the critical role of CIRS in different physiological 
functions. 
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Fig. 1. Inhibition of central insulin-receptor signaling induces hyperglycemia and glucose 
intolerance. A: Intracerebral (IC) administration of S961 induces hyperglycemia at the dose of 3 
and 10 μg (n = 4-5). B: IC administration of S961 at the dose of 3 μg leads to impairment in the 
glucose tolerance as evident from significant increase in the area under curve (AUC) of the 
intraperitoneal glucose tolerance test (n = 4-5). C: Intravenous (IV) administration S961 led to 
significant increase in the plasma glucose level at the dose of 10 μg but not at 3μg (n = 4-5). The line 
diagram below A, B, and C depicts the timing for the intervention and blood collection to determine 
the plasma glucose level. All the values are shown as mean ± S.E.M., and the significance of 
difference between two groups was evaluated using Student's t-test. *P < 0.05, **P < 0.01, ***P < 
0.001vs. Vehicle. [Animals were approved by the Institutional Animal Ethics Committee. The 
surgical procedures (cranial puncture; 0.8mm posterior, 2 mm lateral from bregma and 3.6 mm 
ventral using Hamilton syringe (3-5 μl) and carotid artery canulations) were performed under 
anesthesia (Thiopentone sodium). The tail vein was used for the IV administration of the drugs and 
blood samples were collected at indicated time points.] 
 

